June 11, 2020
This publication by leading research pharmacist Dr. Patrick C. Okoye, with a forward by Dale Nanoli (Natoli Engineering) unveils the relationship between polymorphism in magnesium stearate and its impact on tablet lubrication and drug dissolution.
This breakthrough publication, authored by leading research pharmacist, Dr. Patrick C. Okoye, with a forward by Dale Natoli, President of Natoli Engineering, shines new light on the relationship between polymorphism in magnesium stearate and its impact on the tablet lubrication process and drug dissolution.
Magnesium stearate (MgSt) is widely used in cosmetic, food and pharmaceutical formulations as lubricant in capsule and tablet manufacture at concentrations between 0.25% and 5%. A recent review of the top two hundred prescription drugs showed over 50% contained magnesium stearate.
This book covers a broad spectrum of concentration, from 1% to 10%, for the purpose of presenting their unique properties during powder rhelology, tableting and effect on drug dissolution. MgSt also has both scientific and economic significance, given its wide application in global pharmaceutical manufacturing. And understanding of polymorphism (or pseudopolymorphism) in magnesium stearate and the impact on tablet lubrication process and drug dissolution, would provide a valuable tool to pharmaceutical scientists during excipient selection process for new product development and even during reformulation of existing products.
Preformulation scientists spend a great deal of time reviewing excipients for new product development both in silico and on the bench. As a result, accurate selection of excipients, such as lubricants, could avoid potential issues with clinical batches, product scale-up and product transfer during commercialization.